| Identification | Back Directory | [Name]
2-Ethyl-5,7-dimethyl-3-[2'-(1H-tetrazole-5-yl)biphenyl-4-ylmethyl]-3H-imidazo[4,5-b]pyridine | [CAS]
133240-46-7 | [Synonyms]
809
L-158
MSD L-158809
2-Ethyl-5,7-dimethyl-3-[2'-(1H-tetrazole-5-yl)biphenyl-4-ylmethyl]-3H-imidazo[4,5-b]pyridine
2-Ethyl-5,7-dimethyl-3-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-3H-imidazo[4,5-b]pyridine
3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- | [Molecular Formula]
C24H23N7 | [MDL Number]
MFCD00869950 | [MOL File]
133240-46-7.mol | [Molecular Weight]
409.49 |
| Hazard Information | Back Directory | [Description]
L 158809 is an angiotensin II type 1 receptor antagonist. | [Uses]
L-158809 is an angiotensin type 1 (AT1) receptor antagonist that prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment. L-158809 is promising for research of brain tumor[1]. | [References]
[1] Robbins ME, et al. The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):499-505. DOI:10.1016/j.ijrobp.2008.09.058 |
|
|